MSD took a similar approach with its Recarbrio (imipenem/cilastatin-relebactam) product, which was approved by the FDA for cUTIs and complicated intra-abdominal infections (cIAI) in 2019.
extensively testing each broker's stock trading platforms through real accounts we open and fund to place trades. That way, we’re able to report on every aspect of the user experience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results